GBT - Earnings call transcript Q3 2021 | Global Blood Therapeutics Inc.

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Greetings, and welcome to the Global Blood Therapeutics Conference Call. At this time, all participants are in a listen-only mode. A brief question-and-answer session will follow the prepared remarks. [Operator Instructions] As a reminder, this conference is being recorded. I would now like to turn the call over to Steven Immergut. ahead. go Please

Steven Immergut

of welcome company's and and conference to Immergut, call provide me Relations. Chief call Commercial Farrow, Officer; Thank results to President Kim Executive Officer; on and CEO; the for our and the and Head Steven or Vice I'm R&D. financial Dr. Dr. business are, today David Head XXXX and Love, the Johnson, Ted President discuss Investor a With you, update. GBT's Communications Jeff third to Financial Chief of DJ, quarter Smith-Whitley,

remarks Ted then our Oxbryta will the announcing GBT's call, third will progress give third for today’s review will give up in Jeff this and quarter on update XX, launch, few opening During ended Earlier provide questions. Kim results will an the business release on we quarter, DJ an for a issued press September progress the afternoon, will update our discuss closing before results, financial and financial pipeline, the our a call Ted XXXX.

morning addition, release presentations data six ASH a in the issued upcoming In announcing at Annual press Meeting we this December.

also hold on XX. event for an investors November and analysts R&D will We

our may press are not that I as concerning factors such facts that that by XX-Q, quarterly of statements limited could Before in to made, on made recent implied page this are required contained we be that that, can most the risks including, the as our from our time you results report turn statements undue we this Information to uncertainties. or expressed well reliance statements Copies law. statements. forward-looking are differ at website change SEC releases those passage Future should cause from press today's than such and our to to SEC gbt.com. obligation beliefs and be on time the place any call certain disclaim would the to simply in and only materially as of filings, but The they With forward-looking and statements filings any that of not on remind by release. Ted. other of Form forward-looking are our or events update as begin, statements make on you may Investors we historical over company obtained like to call not are call to subject I'll forward-looking actual

Ted Love

make around the the sickle Thank to you, and the solid everyone. patients mission Steven, of GBT to lives on care of world. good improve and disease transform afternoon, our continues progress cell

well we with potential several We can long-term for SCD both and robust are positioned success Oxbryta, believe pipeline, our for and market. clinical improve which care in further has upcoming expand the help which growth catalysts

decrease this address in cell a compared the Reuter in U.S. to the XXXX Turning new In to as strained. this year. deaths of in the delivered from reflects XXX in levels quarter. in approximately the prescriptions September, QX, This and we to early January. highest were COVID-XX since at headwinds cases the which the August spike second the quarter, need. deaths capacity urgent were was many availability in states, vaccines ICU in despite providers reported XXXX COVID Many news, of sickle healthcare October, in Sadly, early the number diverted surpassed new

optimistic the given subside many remain infection cell very sickle for the where future the tremendous in While unmet in need disease. especially areas we the live surges pandemic QX, in in not patients this rates, did

and Oxbryta We into strong awareness, and to efforts long-term XXXX. commercial give access. education to continue drive refine our potential and heading also us Oxbryta’s fundamental expand confidence

nearly cell evidence X,XXX which for foundational to revenue contributed third Oxbryta each delivering expectations. sickle growing world of of quarter, that validates taking potential patients continues be new increase number the body quarter of patients therapy The role data on will as real disease. Let’s consider following. presented us at The the covering ASH to net Oxbryta our including

demonstrates Oxbryta. research high tried market patients satisfaction levels Our of who among prescribers, and have

results our we our have and feedback of groundbreaking from marketing educational campaign We to the programs and patients including for advertising also Oxbryta. have direct-to-consumer near-term expand positive significantly eligible received and number opportunities

is Importantly, four formulation. date we half new of to approval have action old, XXXX. for In in the approval application our years the December on a Europe, an young as Oxbryta FDA XX pediatric potential authorization expand with include of label market on to patients along first application track as

and normal. growth We are in contribute subsides catalysts growth in these believe of as new potentially the to healthcare year. to to factors position further the return with robust near-term gradually half prescription these second in build We the positive pandemic more and visits XXXX fundamentals on will

In growth. will our fuel addition, children coincide with broad for coverage XX, we achieving which this payer timing to X ages will help believe

advancing We also are will exciting our updates we pipeline have at ASH. and

data supports X potential. we present best-in-class will believe to For we inclacumab, that the new Phase have

present X disease. first pill will from provide our fulfill study we GBTXXX, functional provide data for the potential GBTXXX tremendous be and believe patients. in the see will to sickle positioned for to a sickle these start proof-of-concept for Phase and we volunteers healthy cure in program XXX For to a cell both We data cell this

programs Tenth Sickle together equity. access GBT co-hosted non-profit September, Annual commitment will SCD. demonstrates trends in education, advances leaders community disease through a All this brings launched charitable which of and in that the Conference, community to supports health and discuss the GBT latest GBT’s Disease this September, Also Foundation, Therapeutic Cell future community empowerment, we to sickle in fund that and organization and cell beyond the activity the

people results. quarter our support the vaccine how will is community. the their I This education will Importantly, our are Jeff sharing to were getting of With continue to cell we including vaccine. on call COVID-XX experiences they over on that, review to sickle critical sessions turn and work a part several there to and work third

Jeff Farrow

guidance Oxbryta provided. $XX.X of was consistent of sales from million range for revenue with we quarter third net Total Ted. you, the Thank the XXXX,

given the compared was heading including offices believe months Oxbryta the are in levels we by in This quarter driven XXXB partially a we the second was fourth cautious slight our the could September. COVID of prescriptions remain on deduction, into the typically HCPs On in trend inventory environment, was increased quarter from that number lower half higher or XX%, quarter. rates and to Americans, overall quarter, new to Like the quarter the relatively decrease Gross vaccination be visits holidays Oxbryta, the the reflecting quarter, in in black by increased winter population. XX% in patients increase growing year-over-year. significantly are We the the existing basis, into inventory we patient believe Sales the from fourth overall as to third demand continued driven sales. revenue to in quarter by the revenues as surge the we third absolute new increased, than net quarter COVID by the a Medicaid and growth reflecting quarter Variant. hand among continue Days co-pay second shutdown flat, of prescriptions of anticipated $XX.X most although primarily less base. second new net approximately on and there third continue industry, of offset saw by by and patients Delta continues major lower sequential cases of this also and sequential fourth million impacted in lower on including headwind reflected in the will from the X.X% a lower Third from quarter.

incremental quarter, fourth expect the assumes we third an $XX for quarter. factors, dynamics million. net to these flat $XX inventory Given to of revenue in and million compared increase gross to This range the approximately

increase levels the the we the trend don’t have quarter, history in to fourth While with in year, enough saw prior we predict certainty. in inventory an

commercial gain Looking forward, improves and with to improvement continue see efforts, and growth. traction corresponding prescriptions we a as pandemic in the we new anticipate will gradually revenue more we our as

study Now, R&D inclacumab sales was the in approval basis third with both quarter in for and was low $XX period third consistent million, the million as the Cost for primarily same expense cost quarter R&D thus third for the sales in was XXXX, GBTXXX as recorded XXXX of our the to in FDA studies. margin as compared the Oxbryta were in with incurred expense. Phase to $XX as related expense quarter turning the $XXX,XXX increase the the of quarter years to gross programs, $XXX,XXX to and two third R&D cost events of year-over-year. in expenses. X to Cost prior compared on X of and an Phase well due our XXXX. The related manufacturing of pre-clinical sales as were was majority for

by $XX the in million for per SG&A driven per the same compensation per SG&A including the stock materials with advertising. the quarter initiation period XXXX. roll the We expense the stepwise increase million, share, Basic $XX new the same increase period in GBTXXX XXXX. Oxbryta were was direct-to-consumer in period fourth of the by multiple continue net pediatric supporting factors was the to third same potential in activities including as in Other well which factors, driving non-cash and to loss another advancement primarily milestone million to these quarter million the for for the compared studies, $X.XX investigator of driven $XX anticipate measured and the $XX in diluted for third quarter the sponsored with quarter and quarter Europe into of incremental SG&A compared $X loss as in includes in in was the was this million share We increase share employee-related for expansion R&D The increased readiness same payment in and for other Net launch approval. by for XXXX. costs, and our compared commercialization Oxbryta fourth studies. inclacumab expense increase XXXX pipeline due activities. expense out our of preparation GBT of an third anticipate $X.XX

will to with $XX during over continue cash XXXX. sheet, strong This at positioned $XXX XX, opportunistic a balance and market securities million the $XXX at million compared to cash, quarter our equity well call the DJ. that, addition of million We December marketable - the be of with I from financing includes at the from equivalents turn quarter with end, now net proceeds And ATM agreement. with approximately for

David Johnson

the which progress adoption; Jeff, payer These you, provide for which and give prescriptions Oxbryta. will for metrics number metrics afternoon, insight you in coverage which I informs providers speaks environment demand; patient into our making Oxbryta, that are, will prescribing Thank further update on three access we of Oxbryta, to the an everyone. key good new are progress. and underlying healthcare captures the

by highest primarily in were There growth of Delta progress and offset providers healthcare disease reflecting in many This spike for XXX such new highest cases the prescriptions. with the the September, from fewer quarter the our also and the prescriptions southern numbers wave the in providers teams. had new headwinds our that have COVID-XX and many engagements the and of between patients as of the Variant. First, sickle August approximately driven including launched Delta between SCD recently regions in Texas, Georgia. by healthcare during and spread Oxbryta Unfortunately, the states interactions cell resulted fewer field patients initiatives

southern we away addition, COVID-XX clinicians, SCD some in patients. treat that from order particularly care routine to states In patient were the in pulled saw

fewer the to contributed this of prescriptions in quarter. All new

a growth teams’ communication, the number key forward. they and monitor functions alignment structure we of strategies accelerate beginning levels. regularly and to of our In and confident We drive are on return Oxbryta in new of believe and environment in evaluate a recovery, our patients believe about the this the historical tactics growth are order some COVID change the to to be size brand have We we improve and predictive will growth and return awareness, drive to leading the October, industry-wide think synergies and leader remain fact going to positive believe of operations prescriptions of variety SCD ability improvement ultimately our indicators our commercial that two we adoption adherence. optimize to businesses. we in to the strategies and visits patient prescriptions, in enhance reorganized in engagements and in drivers will commercial I our Oxbryta. As

which reach sickle broke first commercial, in engage with cell their providers. healthcare their campaign patient and to end patient The the well as actual as serves features from of highlights the ground targeted action disease in initial messages clearly its exceeded and at call to for It empower Our month Oxbryta an targeted launched of July Oxbryta kind the of patients its campaign. audience families. the

still about is focus running to TV, connected The measure campaign that seeing including it more multiple media, on social pull-through early are Oxbryta. are information and encouraging While Oxbryta X channels is DTC targeted fourth the pathophysiology will be our signs branded We engagements of to patients a believe team and specialists. prescriptions seeking value we in cell understanding is SCD quarter, cause education. viewed initiating root of HCPs. SCD in fundamental can on with we To the critical of on trained we established XXXX. being specialized sickle clinical throughout our complement to partner education deployed and up print campaign, a They and set on on continue the This oxbryta.com. understanding sickle having activating an for virtual through starting In also team will December are our patients therapeutic therapy. cell actively is do

patients on to and portion QX, HCPs believe improving the branded low the hemoglobin. providing as that impact SCD conducted successfully the In therapy make also HCP having on we the their of unbranded that remain and education another way trained potential third inform continued increases, is Oxbryta improving We patients with is speaker initiate therapy. of important events with new directly also with educating we progress prescription reducing large We to about educating any importance our patients oxygen quarter, In experts Oxbryta untreated their and conversions. branded patients hemolysis, patients. engage to and Oxbryta. delivery, of HCPs are education goal disease It awareness

the easier new from and helping patients on therapy. process providers prior are improve prescriptions speed efficient and make New rate authorization to more the CoverMyMeds, healthcare which like for of offerings us taking starting enrollment

within and During persistence compliance of the stable quarter, the was Oxbryta and our adherence, includes analogs. range which

new are To the In a number in addition, on for further or Oxbryta. support patient plan that solutions we discontinued two GBT adherence, to quarter significant source features of restarting patients fourth therapy launch hubs.

communications patient support GBT how provided ongoing our email on First, program. with our newsletters provide a source we timed the use to information and and access are improving that journey by with to adherence nurse hub

Second, we messaging discontinuation. and on engagements communications with optimizing deploying a by our with reducing focus increasing patients mobile are

And report support strong fundamentals symptom Our patients likely were experience Oxbryta. nearly all continues market form the recommend others. providers also aware research and negatively to the monitor the it research of to improvement in healthcare of disease. Nearly they are have that some Oxbryta COVID-XX that to all of their to patients’ ability prescribed lab to and already impact or plan also their shows future. That maintain to complete continues said, appointments it to works

metric, of Oxbryta Looking increasingly prescribers at and polymerization to health, penetration. which BOC the me characteristics hemoglobin broad my importance see we as such baseline long-term suggesting use, are leads burden continue addressing to provider recognizing and that second healthcare of range

we added and prescribers the in and we the During still total were quarter, Texas, quarter, backdrop, launch. in-person Hospitals by positive trajectory XXX believe about like providers prescriptions visits. writers, Florida of and at is healthcare XXXX the Against states of bringing interactions or to see below both Louisiana pre-pandemic we which being prescribers with continue remain restrictive total cautious non-specialists, since launch. to about for written more levels, in look specialists we When this trend institutions our new long-term the than a the breakdown

lives XX% the to coverage, having prescriptions contributed States. new payer in in to strong efficiency with United coverage This has XXXX, to access therapy. coverage covered more broad patients than we converting of achieved starting Turning in improved

access our and Oxbryta. simplify plans now to patients it and for streamlining We working for process patient program. for process the CoverMyMeds, focused on coverage with receive to easier This co-pay prescribe providing making level to are with physicians physicians includes to

also gaining launch to engagement pediatric highlight are coverage work patient meeting than I in also pediatric teams X team for ongoing XX our population. Oxbryta’s to pediatric with expansion such life and that and experience pediatric adult the team and at related the us I well including science the targets a with indication; research expansion of And development from On to number to at through work sharing ground talk that am payers patients serve through the our quality current of confident to to Oxbryta. This the entire adolescent This pediatric by finalizing expansion data bring approved the from the to for extremely for underway for laying of will in Our patients advancing a access early Kim FSCDR strategies. group is similar presented and and we year with initial can medical faster achieve liaisons; education will the who broad that younger age Oxbryta potential preparation. believe that label the them about did includes large population can initiatives our data medical well potential EAP now as educate years confidence pediatric HCP pipeline. we old. we is X excited note, with prepare our the program; down gives scientific launch want to we approved and benefit market the be old opportunity discuss that, the prepared

Kim Smith-Whitley

to I of everyone. with DJ, today’s afternoon, an provide geographic Meeting of ASH a potentially along Oxbryta. Thank on Annual preview the update you, will data present in and label December, call, and good the at On we expand reach our will the efforts

at will support We efficacy ASH that the three safety and posters further present Oxbryta. of

expansion and now cell reported the includes nearly an XX Symphony patients previously of which X,XXX Analysis, first older. sickle The Claims is ages

third sites. the in is for our durability long-term registry ten retro safety of open-label study. X retrospective U.S. and the from of the and data readout an response of extension second use And The Oxbryta coverage HOPE the Phase updated

cell a We’ve so MSOs our in efficacy world deeper evidence launched we and believe reflecting additional Oxbryta’s to enable recently post-marketing registry proactively sickle real data, safety patients. planned can and share material that use world and of we immediately disease support reminder, our understanding Meeting. retro long-term evidence the this that a provide ASH latest to will real its after educational the update the As

Turning pipeline. to the

X For, we tragically VOC studies initial hospitalization, of evaluating and initiated XX-day the of practice of ASH which compared in X believe The XX-week Inclacumab the is meaningful to Inclacumab, in patients. the the period a other sickle we treatment we a volunteers. reduction of from aligns around collectively check-ins. quarterly will Phase for our best-in-class have named improvement over cell with and two patients At schedule dosing monthly believe VOC, our One an for its study disease data medicine inhibitor as We following healthy quarterly Meeting, P-selectin support for be evaluating THRIVE. of rates reduction occurs present VOCs dosing. a this is readmission of would results VOC Phase which typical a XX% well potential

next-generation exceeds includes data hemoglobin study healthy both single data For GBTXXX, we a healthy hemoglobin volunteers patients volunteer in volunteer our increase In data in from similar and data that XXX. PK sickle our a dose Phase data hemoglobin dose The over observed ASH was with achieved the This first released the present single polymerization dependent to corresponding abstract, we dose range. disease. Oxbryta healthy in occupancy occupancy our today at linear the are cell the from preclinical excited and inhibitor, the with Meeting. in X

to providing symptoms functional exciting this in the data we efficacy range, in ASH best-in-class shows the As many could And level believe patients once-daily cell believe of be trend at what’s patients XX% a damage in all and GBTXXX is this organ that hemoglobin has a continues modification potential plus disease long-term therapy. we pill. a cure really sickle potential and eliminate for

red we the and serious continue future beginning of the As earlier for approval X interest mitigating and expansion, alleviate to the early course disease the to from decline blood also XX FDA up which age patients our believe that review to potential destruction. application We see strong we to protocol, expanded complications modify XX. XXX in to and potential has by life-threatening our continues cells pediatric treatment access

we on remain with review the our authorization of marketing Europe, Turning schedule to application.

be early Kingdom of We programs approval, XXXX. momentum could believe continue with with in United are on we our to building strategic first of MAA and Germany, approved half access France, are the focus importance. of the In which potential a the particular highest advance

potentially Cooperation U.S. for the And on expansion patients approval this and make and next we working in also opportunity are East are are global October, goal, in outside Altogether, XXX,XXX Council patients intended such Gulf over ahead the around in plans schedule more received make continue our in than and as resource We United our to America. Latin first approval the years. to we available In Emirates, to the Oxbryta of Africa progress Arab give Middle cell the filings. to also And in explore Oxbryta world label region, sickle therapies the our will of reach we to us strategies bring limited the against regulatory our we to several as geographies India.

Finally, more next access our we and be therapies R&D gain our Day to innovative on activities at will pleased pipeline our week. to share to

the panel experience sickle addition In host landscape. children back the to just I event sickle its pediatric a experts of the into and will And with with it discuss over a a patient sickle I Oxbryta sickle therapeutic went their that, with place provide a And disease in the with journey cell of mother and will I’ll who cell turn include disease chat to disease will three cell Ted. cell over, to insight fireside advocate experience. research and

Ted Love

Thank leadership cell and long-term continues is in you, for GBT disease its closing sickle success. well positioned Kim. In

and adoption awareness opportunities prepare Oxbryta commercial multiple are to we We of tuning ahead. fine for as continue our growth activities and drive

more COVID-XX end progress to we disease an is progress. impact, to has in vaccination. seeing and continues are sickle This an our disease, the come received will the COVID-XX making country community have While pandemic impacted people cell by

as communities patients. to of improve our to forward, stronger we move we than strive ever the As the supporting commitment sickle lives cell GBT’s

we end that’s past celebrated I want As thank take involved highlight been a the recently the over to anniversary. year we I year, that to to everyone success ten our the decade. moment want our approach of with

have week Prix incredible recognition Galien significant for to Award with Best Products. receiving are Biotechnology progress the the We impacting lives We Oxbryta truly for made impact USA this patients. positively received of Prestigious a and be grateful very last

of most until Some lost of hand original to many. move cell It and discovery Yet disease. providers, a to GBT and of a is a passing patients. investors Sadly, as in were not far we receive stop cell powerful battle was On healthcare the presented cell passing I hope to and of all depiction Hertz of achieve advocates, his have days transform complex in the young well. and our the receive Oxbryta beautiful at well-known honor in Hertz this sickle shortly this office by come would like well-managed companies patients few goal. uses We result we condition. and a which and his everywhere, advocate teams He on disease work sickle personal a Hertz future for sickle to GBT to who thereafter, will City. a award wanted for sweet behalf his knew of is so artist the together community and patients, Nazaire, cell our to collectively before York us, behalf New in as learned forward Hertz it. on raise a warrior and the hard awareness of to of tremendous award with the an disease sickle his talented it too installation, know battle was bitter we artwork patients

was call on Now we the Scientific morning. Officer ASH for Chief briefly Brian GBTXXX invited our Brian? by wanted comment abstract I’ve the that us. to open this join questions, Cathers, before we published to

Brian Cathers

everyone. Ted. Thank Good you, afternoon,

in As Kim potential excited for we are said, Ted GBTXXX. and the

actually single Our XXX two of doses studies, one multiple is looking volunteer healthy and a abstract XXX. at includes ascending doses study

versus hemoglobin the is we discuss volunteer am looking in we measured dose, for single a volunteers how under at and going to hemoglobin doses second From occupancies at the X,XXXmg mean With in was occupancy occupancy data percent I mean interpret XXmg, SCD healthy ascending preliminary multiple single single healthy preliminary patients. single each XX%. of the This At dose just XXX levels. was hemoglobin data. the dose, reported occupancy exceeded this range. the Voxelotor XXX together plotting When single trend with this additional with single for mean the this the for a graph, What multiple on with data and long expected data life be half is doses study? receiving as Voxelotor drug, does which than dose to would data dose dose the The study and Voxelotor. steeper similar separation In line well occur X%. multiple healthy general, as patients. we the definitely of data over the the dose saw a in that volunteers

of single patients. is was was abstract wanted study to GBTXXX has Disease, Voxelotor well-tolerated of also comparison correct February to GBTXXX and reference title, that published SCD Cell Voxelotor Pharmacokinetics Patients study the in the the the I the error. Adults published up, With that volunteer to to Pharmacodynamics Journal I The support wrap in which mention Before publication Sickle GBTXXX also clarify Healthy healthy and those dose the of I XXXX. Clinical British in to Pharmacology in wanted with of the and

study is the With there before, study, this AE X that shares believe our have While best-in-class which serious Operator? If potential excited range ongoing. to Phase open data patient said the the as questions. Overall, was encouraged we GBTXXX drug. this we we and the trend AE have are not that, in plus study cell the we to are could therapy. seen data we in healthy XX% for are continues hemoglobin healthy healthy seeing sickle volunteers, we’ll be related and now a the call volunteers modification one continue by was in in volunteer

Operator

from The of Gerberry Instructions] question Jason Bank of Please go is ahead. first America. [Operator

Jason Gerberry

guys. my model data. taking for Townes previous Good do the XXX, Hey evening. Thanks for data question to animal has the question. My with

the what past response this guys you I the to may think was. addressed forum, forget I have but

I So it model. assume looked I And are Voxelotor hemoglobin similar versus saw I that Voxelotor if again. occupancy know Voxelotor isn’t the just you how in XXX? in at to that publications in animal consistent because versus a am am there these in Voxelotor the using arm. with going you I improvements ask increases ultimately, XXX, wondering, just you in clarify a could receptor

Ted Love

but with it’s species sickle unlike In a sickle tested, So, complicated, Voxelotor Voxelotor, exposure. unpredictable mice, every bit cell cell we’ve mice. has little in other only

occupancies target So we occupancies, get can’t that like. the the we

achieved we Townes So in animals in in are some the what with able occupancies. mouse see achieve do doses, the lower significantly the model. and published is occupancies target studies - robust target But the we with see to XXX did Voxelotor, comparison responses we several

In with addition, Voxelotor. compared significantly efficacy greater as we similar see to XXX, at occupancy

Jason Gerberry

it. Got

Thank you. Okay.

Operator

question next Jefferies. from ahead. Please go Akash The from Tewari is

Akash Tewari

Thanks much. so

data five effect than kind times in dosed So, you is north if going we today, get fair XXx healthy a are getting threshold looks hitting the in of terms shot are of more the we simple that dose, we modification goal the math Oxbryta to And than potent at downstream all look three MID Oxbryta. lower if really and get with hemoglobin. I XXX the XXX about it’s guess about doing saying and to XXX in on XX%

dose twice state modification. loading applied the process accelerate mentioned getting to about will be it talked you’ve the hemoglobin you’ve a that steady Now and basically will and

XXX? you’d for and ability data on would will XXX’s loading with that feel in, details be A, be then, an maybe on is ASH fair read can make you. at if Day? and And applied and the be a to accelerated modify do we dose you think comment on the also hemoglobin the pursue that So, at how can HPS? R&D And increase if to it what I pathway you Thank if approval XXX this willing

Ted Love

followed that maintenance by And recalculate data will a that a off but get designed those Akash, patients saying is, Yes, of another them was get loading we loading same questions, and couple single and the I’ll this then dose dose. study that is way then patients the start giving will followed at dose dose with a another a will by dose. maintenance we look

really therapy goal, goal really to you know on concept hemoglobin, we We So that’s with to XX% get non-sickle dramatically. have – Crispr are and the here certain levels to two prove. to trying you mitigates in the Oxbryta gene disease that And we will the that already of and if modification. this and shots once get

out with with So, a concept here that to figure to daily the be plus compatible is low XX really pill. get a very would once percent can if dose high levels we modification, of these

to make conclusion that think in or prove not ASH. that we really that’s strong we do concept So trying are we’ll that position and the at be a to

bunch a So rather what a with we have said regard going my talk approval, terrible FDA, you’ll the good discussion, is, that’s always FDA, the some to development I’ve With about to good data, that. having discussion, and drug of and feel hypothetical career. to accelerated in get than a

strategy we FDA we will thoughtful tell really the So, about know, drug. want right then understand some on start so development and we now have really the getting we talking our the we discussion the put go and quite it. that we to talking will before before with don’t focused a card strategy data, about frankly, our development horse, much about about you are and Oxbryta But then,

tell in So, this I accelerated we will am on thoughtful personally proceed to you not way we good give that focused point at I full a just can trying leaning you an am with very strategy. a so more are strategy, I toward approval feedback. approval this

kind possible a look may basis data about like. might really on get be what if may. making speculation that we but am efficacy we we the the anticipate I of statement the that that’s again, of data, no that I think simply But profile

Akash Tewari

much. so Thanks Understood.

Operator

Alethia next Cantor. Young question ahead. is Please go from The from

Alethia Young

taking for like as that the on that’s reduction? Hey VOC And dose, How and you kind guys. Thanks you like from with of with the more that there Galien, translates is continuing again award, XXX, is more. be important it something multiple importance question same a my awesome. seems levels will that it I you than standpoint? think into was show it guess, do think regulatory the seems has apologize. XX%, Oxbryta of now single obviously congrats with doses on It I Prix the

Ted Love

I actually the red Alethia science Oxbryta say by is to a would causing I Kim of to and and anemia. polymerization good the is What It’s Galien think is predict. question, and this. add as Yes. follow-on anything you already That and sickling that demonstrated with would destruction that, is cell we’ve hemoglobin blood

of If as all declining. that as the decline rising, quickly well you measured elements as hemoglobin intervene see with destruction the Oxbryta, and red reduce the very polymerization, cell hemolysis you by the can

already this know. So, we

in that also the decline. response in dose study, a look at if the We know VOC the HOPE manner VOCs you

not – VOCs the more P the effect very Oxbryta, power and clear that did design not We that study around values, you down. that go but give have as study we is apparent

fundamentally red drug think a interrupts create again that should correlated less by decline that the inflammation vassal In events with the higher is that less cell of and associated thing your if with went, the inversely polymerizing occlusive time words, you a other with sense, because VOC should hemoglobin is more driven about makes that a it disease. decrease this other the lower they destruction, this publish disease is were which rise over with which healthy VOC all your the are Hemoglobin went. co-hemoglobin, we The – related.

lower. hemoglobin, levels are to would modifying expect hemoglobin we to actually are reductions So, together the I and if think get VOC to the the be all be very with we Once studies and XXX fit expect. more would higher likely we we signs to well bigger

that We remarkably know prove consistent. But has all have prove and science actually we to to all we been that. the need

Alethia Young

you. Thank Great.

Operator

ahead. Please is Breidenbach Oppenheimer. next from from Mark The go question

Mark Breidenbach

Hey, my good Thanks afternoon. for question. taking

providers DJ what lung versus actually between going quickly am they be a surgery occupancy? are they much volunteers maybe then, is in pediatric going am adults, just just dose we get hemoglobin cell your the are I And are wondering ASH comment differences of to on major for terms healthcare hemoglobin just that things and wondering to we you. Just if dose any to occupancy there multi in to trying then, to an Thank can sort? patients I how of very get of single in healthy data target me, see overlap presentation I you’ve for sickle in already be am if just sense going doing or been

Ted Love

Kim, multi-dose you about DJ want and do the to ASH XXX about will pediatric talk take launch? the question

Kim Smith-Whitley

for thanks question. Mark, that Yes.

data our is show that multiple dose sickle volunteers. think cell intention I healthy in with ascending disease in individuals to

David Johnson

DJ. this Mark, is Yes,

as our expect. are fledged full good old approval and preparation majority the And XX% United therapeutic geographies Regarding we would specialists. The and are potential launch, in and also are patients news physicians those is patients the launch in mode sickle treat States the list called in where already in on. that – the pediatric of cell vast X pending the years have you so target between of XX we being already

We are XXX expanding and list cell really XXX are have about on and specialist those our incremental at represent the target XX anyone by don’t focused and kids sickle currently that physicians approval only older. younger

target our to reason in list. So be no there current would be

pediatric with of group very of So already got vast and it’s expansion the majority hematologists. other small relationships a we’ve

by over the But the XX in on our being with years course they with teams, feel and broad about get of our So preparation we older. same patient educational sure launch that experience preparing quick are fronts the plan can coverage in to good payer all of that, we possible, really as of having couple some developed. and the making have the Oxbryta great that is and access payers, and work last support we terms initiatives many those services as leveraging meetings,

we with consistent a formulation. and we And with XX older kids. but did So, course all launches things will of new the those of towards – course, are have what the be then of

formulation for and a materials around that themselves opportunity do great education make to some have new some and the the the care kids to it’s creating education. sure So givers us

Mark Breidenbach

Terrific. Thanks much. so

Operator

Paul is Sachs. Please go next Choi The ahead. question from Goldman from

Paul Choi

think population defined next you and very around patient hemoglobins appropriate far from your you stage have insights a you’ve patient afternoon much. here extremely abstract range, on visibility regard Do do XXX more to that the you is sickle and as with cell Thank hemoglobin? this for Or to about narrowly still be good relatively applicable patients think with in a indicates what population? but you at it Thank patients dosed. question the about severe study do The everyone. you being point? low what do XXX patients so would feel potentially is baseline you – you My have wide

Ted Love

Yes.

you reactionary. it. were mean, heart decades to sickle I disease. what we still in Paul. treating quite think are people to are question, great has ago, begin to hypertension. been frankly disease trying a to do on where we of we XXs. in I want in And stroke cell of think their It’s I the been drugs a these treatment that’s dying in couple attack And situation a don’t way – I it’s the wait about really have So, or are

You reactionary not you are to approach. probably change a have if that going

to when X and their XX%, as the with X, not normal we children intervene of levels. opposed already may wait of go is intervene X kids be modifiers in suffered to very disease I to down reliably in somewhere around for are children or you able and decade the that developing hemoglobins normal first them XX% in you running when to to those in you that to you that’s try keep of correct of early know sinovenous you XX% ischemic life. disease do And range able or have strokes accumulate it mean, anemia the point to whole the be So, and still may essentially people if are to early. normal do

that why about it. if sure So, we’d could something do with be not we I am contained

Paul Choi

much. Thank very Okay. you

Operator

The next from Lee question Joon Truist Securities. Please is from ahead. go

Joon Lee

you have certain I idea And you to do as will need the avoiding thanks oxygen to benefits riding Hi, percent a think weird our occupancy most extract for side-effects? to potential what any But hit you start have couple. while taking what misuse percent to potential? to hemoglobin interaction you questions. therapeutic

Ted Love

all humans do the we we It’s get that clinical are understanding figure that toxicality one an studies. of of when is what risk the are a I can Joon. try this work clinical drugs you your question, look to ultimately consequences But to to that for you the doing right, reasons mean, this go we Yes. great out. work, And have to likely into before do and actually the of

the work done tolerated. it’s XXX% the hurt we’ve hemoglobin XXX of animal. not very actually amount We and is, an pre-clinically truth extensive of modify it does So, well and

don’t likely life we So, roughly humans? will in that to huge in we modification, they back and I true hemoglobin. your people sickle half to cell hemoglobin. predict a be that would because need XXX% roughly of trait modified simply know question, and dose you we’ll normal XX% able know. don’t medical earlier were expectancy of be we with the sickle We of to to a the hemoglobin XXX% would people think be phenotype imply I And a coming trait cell modify that would into a more have that don’t sickle advance. convert might

certainly to higher on to not a set and that we data that as to is. XX%. But get think Kim, want need XX% have easily can of get want still some you may to we to elaborate what need precision we we threshold prove So, expression target may understand exactly the those indicate to that you of we hemoglobin, XXX.

Kim Smith-Whitley

Yes.

individuals are of you relatively studies with precisions and levels hemoglobin I at XX% through stated that hemoglobin a think of asymptomatic you state. that and well, get We know Ted. predatory sickle you

think XX% with. getting that it nice approach a between there is So, we and be I modification conservative XX% hemoglobin may

Joon Lee

in Got maybe opportunity just the organs other than spleen more you. with on. you have fact, since earlier population, start opportunity few skeptical? any in question, organs you read do in the you with show damaged it. Is pediatric I modification, benefit patients earlier one disease And the brain? that there other Thank an maybe if that to squeezing mentioned

Ted Love

the which think I right is involved hub in great Well, question baby she that’s study, Kim, are going. a for you since was

Kim Smith-Whitley

Yes.

think I excellent question. is that this an

is organ functions. One the to of a proactive impressive preserving that about reactive approach possibility is than the a treatment things of rather

function can that and I early Phenazone in we’ll early be organs on the is why is be get which in life. we so of organ spleen know, into look to life, faster, one relatively to And think need the preservation placed see so, groups we many dysfunction the able children of age younger at where as you

look So, spleen at the optimal really with. may able that organ start I to preservation and is agree organ be with you we an to

Operator

Gregory The next from Markets. RBC Renza question Capital is Please from go ahead.

Gregory Renza

progress and a Hey, on of and commentary. question. my Congrats taking Ted, Ted good thanks DJ’s some afternoon, for on the team. maybe just follow-up

market those actually out those much. therapy? clinical just that to you the – you you prescriptions typical that when perhaps playing DJ, the Just new interactions. that respect to mentioned on elaborate if you to that how of with converting escalating the could Perhaps see dynamics lag if indicator it you especially if very of further this could seeing just patients being curious just are some with and Thank comment are start I you respect end time into comes we recall, seeing year I think,

Ted Love

for it DJ? go Let’s

David Johnson

Greg. Yes, Yes, for right. the that’s Thanks question.

middle it. dynamics Delta got So of seen the right. great lately are pandemic, we to but in right surge, the the asked regards QX, in marketplace really We we’ve some with in Variant the

in number they Texas like of and QX there get beds sickle XX% top sickle use sickle in states highs number and for Florida significantly the rates. five example states states, if because over and had three in bed But cell entire of look surge. infection of cell increases, pandemic. in Certain states September, two the So, not QX like and all August their time was the infections ICU Florida, for during Texas all in utilization you ICU key only the cell at Georgia,

all So, included that sickle visits patients. patient of impacted and cell this negatively on

rates African is right worse. QX, a that Americans going do But feel our it pandemic. people system two and CDC races unfortunately little this in rates other healthcare the although are the vaccinated. more behind what’s going the In vaccinated there being it’s in and before direction, the in Unfortunately, at back not when of most website got at So, people country, vaccination things weren’t only us QX. to confident in important we look are bit into the the getting show terms more still in lagging are they people actually they were are

parameters little look QX. we below basically is rate the So brand at the they kind sickle then, is at where the which sickle And was the seeing look are, the worse QX metrics, and thing in audits below it you on the because other the was well not still if We to States. And audit insights and QX bit their into, claims surge. prescription two patients that industry and look pre-pandemic a we cell of healthcare industry-wide United got drugs – it’s levels we at new of new than that, at do. still worse we the is were and disease levels for that get are actually providers cell they pre-pandemic same databases in that’s at specific look

to So We audits things we that are QX, hopeful look once – in turnaround. start quarter. those a will at

in in So, we a that will But for headwind look QX, QX. at clear it was again us.

Operator

Morgan next Please Stanley. from The Matthew is from question go Harrison ahead.

Matthew Harrison

sorry on evening. Good to here. one taking get Thanks am question. you XXX, from another for I will but dwell me the Great.

some in of you do you takes was in irrespective with was, that normalize So, hemoglobin lot to data in Mice, mice what those obviously and previously it guess, in I hoping of are longer, presented doses. lower a I mice those data specifically

you at need you. you think able follow-up data long just do do Or data going that the have Thank we longer see in to would question enough are to out that? follow-up you be to you to my humans? going pour ASH, able So, that be, are think be to get to

Ted Love

Hi, didn’t question, translates and on earlier modification, modification you’ve read in think educate thing that notes. XXX excellent want the because I Matthew. your regard of into. focus today actually to I to With is lot a the your And what real your on think we wait note people lab to actually points I But animals thought I with The we organ made we and treat very and damage they early. the there We to about accumulated is nice we very, lab is these lab equivalent the going old, be intervened to years it to and animals, be thing ten variability. same basically to very animal began that, early. are

between an of you in quite what modification. we’ve modification But very that and young variability get eh that’s I that just intersubject correlation think you of same the I may So, to have hemoglobin it with is published response. level tighter possible based a the will tell be on a individual bit already

are that And than upon in, more we hemoglobin So doing have the so of think obviously I the on you patient more modification, are to every that really educate higher in you and will on average, modification look be are VOCs anything other all I of think the to enough our at really of proof-of-concept regard. things going well. locker and data don’t enough to probably proof-of-concept initial more really well enormous to achieve in also hemoglobin. focus as will is much achieve the we else. and variable to would outcomes and some modification going study VOC like on studies correlated lower with modification It’s higher you have presenting patients, analysis favorable we data we as that which and with not like relying we be even that body focus with levels people as response hemoglobin says But

Operator

question is Evercore. with Please from Maneka next go The Mirchandaney ahead.

Maneka Mirchandaney

the question. taking for Thanks Great.

thinking was And up what’s level to that on at levels even wondering if the the occupancy just saw you be start ASH, to after What consider was of that level occupancy and as XX% expect on we this dose? morning. would that the peak then, XXX should measured the at. ASH? drug in expect data point above you would Thanks. am see the the Just And well the we occupancy time just and cohort going XXX, I – kind highest dosing? of PK to of dose at the it

Ted Love

can you take Brian, that. So,

Brian Cathers

part, about at we are occupancy talking the the first peak. Sure,

drug dose. a single a after life dose, with actually measure very of half the But dosing, any multiple CMAX What we that relevant to long has more want with single because days CMAX, So us. are CMIN similar. it’s at you to a expect it’s the for that’s look just,

Ted Love

that are of be. life what peak that dosing is time sure that’s make multiple be to state expect half half be very long would will ultimately be going with steady is life the just So, is the trough. to and that that expecting drug, difference very what still amount And Oxbryta. there profile But what a with with will very clear, over half very drug. underestimate drug an you life long a to we of with peak a for likely the that’s a longer And small

it’s pretty hemoglobin approximate better of these steady because So much modified. gene excursions of activity, of much of getting is will how really are you if you you are getting modification, not a state

Operator

from Prasad Please The next question is go Blair. from ahead. Raju William

Unidentified Analyst

This [Indiscernible] is for question. Raj. Thanks our there. on for Hi taking

sense get to the of a are trying We the label. pediatric potential better launch into

better who you indicators, of distinguishing provide ages the number And we plan compared original wondering treated. post-approvals sense already the when could I on get any then, patients label? can a providing being launch was on XX if color to so current of So on you commercial if XX any are to

Ted Love

I how I’ll break therapy. patients they don’t fit ask into past. group break we mean, actually But in the reassure I provided on logically look the think DJ But down many similar. we take that. on provided current But haven’t of we could have patients fairly speaking, down provided would age that on data we’ve each and to that. numbers

David Johnson

right. That’s

high call little physicians can growth have it basis. – our Oxbryta. specialists and highest both of in the depth of age prescriptions of a About XXXX tell that half of list written way. I target have We we opportunities that by haven’t potential kind we on out and over decile breadth a we for prescriptions the of half, you feel a that about do regular physicians broken of

pandemic. still grow to patients physicians this overall, about opportunity their lower patients. access the to So of second access some prescription written and a tier and into they But patients for physicians educate educate to there as Again, their them the have mid-tier during have a only of of group ability to somebody to Oxbryta. speaks getting to a third

have lot in XX So they the Oxbryta The both have we older. areas. that of have to lot and of opportunity extent and X pediatric great kids pediatricians those in between experience only have hematologists XX. a written A of

kids to they’ve for opportunity it those and really been on to. holding that they’ve they tell So, got write us

after So, it’s us an opportunity soon launch. for

Operator

The next question Baral is from Ritu Cowen. from

Ritu Baral

thanks guys, presented a constituting in made for you the question. I the that that know early pretty thinking wanted and the in Ted, to you also the ask I want Voxelotor were Dave, occupancy, about focus development. about am functional other the on one comment about – taking biomarkers to cure you but I

would of For change, this to Smith-Whitley what LDH too. Dr. love and change, could I that mechanism, and sort constitute damage billirubin outcomes sort of other hemoglobin reduced VOCs? change question what above improved organ beyond just ask And

Ted Love

have Ritu, to follow-up clinically look enough we patients kind think I But that, outcome will and to at we look start have reliably completely. study don’t enough levels. I enough it patients and answer should even any by meaningful of this saying Kim don’t hemoglobin just maybe Well, in at

you you look at if had the as people four some deciliter. think other for gram per patients know modification the I level half of patients, response a wildly deciliter, just study, per HOPE with varying same hemoglobin three grams

the at the X,XXX to the around having size. if you arm to it way that. better for of is dose you see mg hemoglobin it’s a But dose, definitely response total So, the But XXX see get response. X,XXX. And that look that’s example look larger XX individual. by mg with that was due sample you and the data, there and the per hemoglobin you But a at in patients overlap a when lot the

has So outcomes the get we really problem, to you going like. start hemoglobin in looking are that really as occupancy pretty there. with that Oxbryta other will But we as powered not it way quite is and direction occupancy, want, hemoglobin we because you good be predicts at a the in feel

free me. correct feel to Kim, So,

Kim Smith-Whitley

sometimes really that individuals therapies, even and but a of have gone population mixed degree individuals When very curative not at normal just you normal add LDH I free. become even hemoglobin who of even who understanding to difficult the want look the on it’s don’t through achieve values chimerism, study. you have depending we symptom values

this been continue in I So, and is trials. study really will we we even and haven’t therapies, hemoglobins to curative with think that But the other to something that kind we learn more XXX go with consistency of arm relation as what cure. about to mean clinical find biomarkers able through

Operator

from question next Partners. Please Yatin ahead. Suneja The is Guggenheim go from

Yatin Suneja

guys. Hey

upcoming date approval or upcoming the on question for a you ask me Let kids. PDUFA

in addressed I a your kids How could I you talk it about quickly wrong. in be then, terms perspective. can And goal reimbursement uptake you of think adults? And the am if view me versus but little reimbursement from just then, achieved? correct bit,

talk new I this added? how think number will add be many Thanks. approval just aboutXX,XXX exactly patients label. the will Can about you the patients to

Ted Love

for Yatin. Thanks question, great. the That’s

DJ those. address ask I’ll to Now,

David Johnson

and year pediatric original Yatin, for already three Yes, where the guidance in good because high older. even approval because news will a broad accomplish clearly will XX we coverage line for The in is perspective, a and we we’ve so, the majority from it’s patients XX of this consider with Oxbryta payer Remember, quarters. of the a got they Oxbryta the extension launch states is, than the gave need, discussions faster and to we go and unmet payer in recognize to expect older. get one Okay. that

faster can’t still. We expect this will that. give. a dates, take It to Exact process than be bit I a

existing whole in brought NDC that But will a the a an There new statutes You introduce to require market. of extension some are states do extension product, their a reviewed product on have go line as quicker. it get is formulary. go we does Medicaid a through time process few review even that do require have to for then being to every a line the to to get

you be to are months by review will we able like, ones faster XX feel to So in and large, we will those like accomplish process a the formulary. were be bit that than and to this and for adding then for six little three older. But slower

the terms you is name In years yes, kids are people for market, game. sizable a of to starting earlier size about Dr. the reasons between organs and old. and the important XX,XXX of XX,XXX Smith-Whitley X of protect XX It’s talked right. all very the to group

educational So, older our on pediatric our already the list, we it’s hematologists kids because even a in the go And than increase faster sizable with target label. efforts as we that the they are to are well. think calling did will

Operator

Please question ahead. The from Ben Burnett Stifel. from next go is

Ben Burnett

patients versus going question much. and some you have discussion And hemoglobin like ask you in maybe to the then healthy achieved? available Hey. And volunteers, I a earlier time XXX hemoglobin can ask repeat points difference from what what wanted multi-dosing? is, And is I also the the between around to about dosing? very Thank just what back your dose do you translated to Oxbryta occupancy really of this with single what guess, way to occupancy. with how into was when we you dosed expect like single experience you that a

Ted Love

our is actually effect think send on then some This Ted. information get, we website. may out I Ben. Hi, We

and gave life this there we we to difference going to So to are comparison. multiple feeling and about very you dose be low longer. if the about the and do at to say, being haven’t look need gotten just able get I’ll And becomes there we subtle. just XX a get percent a But getting perhaps is plus there We we very we data. can that feel big to good But between are with very that even is difference to want the good we are show But a to dosing. go yet. pretty modification to. the get single that and modification What that dose you what greater make that website not sure

Operator

James. Raymond from ahead. from Please is Brill question next go The Danielle

Danielle Brill

the the I list will add Hi guys. to Thanks question for here. on so much XXX and

a Another ASH I hemoglobin XX% sounds a expect the at like the be on hemoglobin bit variable you am you see and hemoglobin between you then it will occupancy follow-up guess, and small think and hemoglobin the can magnitude it’s I plus elaborate changes end. on of correlation if would at change modification wondering to improvement. just

read XX% like fetal effects XX% level? hemoglobin Thanks. can’t much more with you would generate that as hemoglobin XXX similar it hemoglobin So therapies modification we would into reach that and expect gene represented the population that

Ted Love

Well, Kim my on hemoglobin if levels thinking the to I been this, about outcomes can that similar. therapy, we of I mean, in way I’ll that of gene defer be to has non-sickle match Danielle would this. But expect

we but know that is with curative said, hemoglobin Now, individual. strong. we their response it’s can, not sometimes has and biology and need be sometimes our probably do But variability as of And would people as this. to prove of get that the that to very that the Kim all strong anticipation, procedures do of

X,XXX get using with the average the modification they deciliter. I per can X.X, that and was the mg put through beyond will study Now big, pretty variability HOPE just where grams you by end in context X,X about in begin it

With it dose, was the XXX mg X.X. about

but those see are look big of difference, there to you So are a overlap. individual is lot patients, at if you going pretty the

difference difference randomly of quite patients, pick know XXX even big a not is six there we and see just between you X,XXX. a much though may you If

Operator

anything. Canaccord. from line The can’t from your John go open. Please We Newman next question is ahead. hear John, is

on. question Please Wedbush from Andreas move let’s So, The from Argyrides is next go Securities. ahead.

Andreas Argyrides

evening Hi, taking for and good thanks question. our

on just want friend. condolences the Before offer to I a I start, your loss of our quick,

about Sorry to that. hear

Ted Love

you, Thank Okay. Andreas.

Andreas Argyrides

Yes.

update. is for look XXX because I This not question, forward you. everyone to probably to Sorry it’s DJ, asked. has the

a has then the the those call And that last above - in XX%? get from metrics update kind and the XX%? as prescriber far as and the increased then, rate with also prescriber existing ultimately I wanted of population, on that Just Has just an penetration restart. some of who into improved so number those, discontinued to quarterly discontinuation you provided Thanks. on sense patient base that

David Johnson

questions. Yes, thanks the for

It’s as several Regarding quarters. the always range. within restarts, said a compliance has also discontinuation restarts XX% XX% the well rates been the want has first the adherence, well as both end be first the and The we’ve at which discontinuations, includes analogs so last to end within and of year consistent. and been at year well that the between – stable of we of the patient’s are we for

of future. therapy over So we’ve some point several plus in at quarters XX discontinuations, restart last percent seen the the

it’s their to range penetrated And I top we penetration prescribers And the at mid a terms We know then prescription so the of XX as written penetrations patients. we well. list, think now, that for that continued in in high are in are have XX% I’ve writing QX prescription Oxbryta. somewhere target doctors the XX% our now. highest for our it over, of like

getting about So, continuing providers. we like now looks just and education their it healthcare patient and it’s the access to know

So that those can increase we rates.

Operator

The is Yanan ahead. Fargo from Wells question go from next Please Zhu Securities.

Yanan Zhu

what’s globin consistent mentioned I Thanks for is XX% taking my editing questions. between pretty level gene therapy, in in traits different Ted, non-sickling XX% globin is non-sickling you the the individuals think studies, gene studies. and

about it? level are study? you also something the And confident related is study, XX% is do a kind can the reach XX% occupancy Is of that importantly, with to that confidence the is cure VOC think think that of is, – you a and functional to right current and the receptor lot question give other measures? in that within way my of equivalent So, free that

Ted Love

Yes.

set they’ve on But And got cell good at of like Yes, at a either a we disease to with elaborate hemoglobin, kind normal this significantly reason. for question. So, it’s XX% look it’s sickle cell we’ve around look began excursion actually, that than more XX% it’s reason. if could actually the you persistent individuals disease. sickle

to do. But you, know and back out had they So, this the of seen gene these dramatic have XX% they go the you effects experience if But wanted than I I efficacy below some at that, my they getting above gotten or what when example, they that at you data, XX%. most I with were weren’t when – when their really not have therapy levels. were look exactly recollection gone they’ve they’ve XX%, may and they kind XX%. agree Kim, is better parsed above for they

Kim Smith-Whitley

Ted. No,

you stated correctly. think that I

Ted Love

are effective inflammation anti-inflammatory that’s the that make is drug it one that Oxbryta patients other know get of would probably one developing about So, is be of things it and VOCs. that, that and are is highly driven that is not anti-inflammatory and an we point VOCs the drugs. significantly treating disease the reasons I expect we in XXX sickle we will inclacumab the by cell are

we any significantly So, wouldn’t anti-inflammatory anticipate effect.

the therapy that a that, will resolution and and the So the inflammation ablative with between mean, outcomes initiating is it’s I about delay associated we of there things highly of expect symptoms do and therapy our one be immunosuppressive. inflammation. with therapy

In fact, that’s what you are doing.

not the received HOPE completely and and immune But to in get decline. time, of course. in we pound filed are You the the system will the inflammation and effect, as which anti-inflammatory it wiping immediate out, they VOCs per you digging significantly logic would we expect you when do therapy bring study, over we with experience, our

Operator

I concludes to the back turn would closing Ted for the Love comments. session. This and question over answer to floor like

Ted Love

virtually. everyone all at of I safe, stay feel any if week, to free many questions. we out the look are our time, want healthy Day many forward to reach just closing, as want you well you to In as thank to R&D remind I you In mean seeing for additional of also please I’d call and joining to the there seeing that like next today.

Operator

today’s concludes This call. conference

You your for you may time. Thank disconnect your at this participation. lines

Global Blood Therapeutics (GBT) 5 Nov 212021 Q3 Earnings call transcript